婴儿期卡介苗接种未显示对COVID-19的保护作用:瑞典自然实验
该研究利用瑞典1975年停止新生儿卡介苗接种形成的全国性自然实验,比较1975年前后出生队列(分别1 026 304人与1 018 544人)的COVID-19病例与住院情况。断点回归显示,COVID-19病例的OR为1.0005(95%CI .8130-1.1881),住院OR为1.2046(95%CI .7532-1.6560)。研究可在95%置信度下排除普遍接种卡介苗使病例减少19%、住院减少25%的效应,认为中年人群婴儿期接种卡介苗对COVID-19无保护作用。
要点
- 婴儿期接种卡介苗对中年人群COVID-19病例与住院均未见保护作用。
- 病例OR 1.0005(95%CI .8130-1.1881),住院OR 1.2046(95%CI .7532-1.6560)。
- 可在95%置信度下排除病例减少19%、住院减少25%的效应。
核心结论
- 婴儿期接种卡介苗对中年人群COVID-19无保护作用,可在95%置信度下排除病例减少19%、住院减少25%的效应。
研究设计与样本
- 瑞典1975年停止新生儿卡介苗接种形成的全国性自然实验,采用断点回归分析。
- 1975年前后出生队列分别为1 026 304人与1 018 544人,记录COVID-19病例与住院数。
主要发现
- COVID-19病例OR为1.0005(95%CI .8130-1.1881)。
- COVID-19相关住院OR为1.2046(95%CI .7532-1.6560)。
- 可在95%置信度下排除普遍接种卡介苗使病例减少19%、住院减少25%的效应。
临床怎么用
- 不应以婴儿期卡介苗接种史作为COVID-19防护依据或风险评估依据。
- 近期接种卡介苗的效应仍需另行评估,不能由本研究推断。
局限性
- 结论针对中年人群,不能外推至其他年龄组。
- 仅评估婴儿期接种,未涉及近期接种的效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The bacille Calmette-Guérin (BCG) tuberculosis vaccine has immunity benefits against respiratory infections. Accordingly, it has been hypothesized to have a protective effect against coronavirus disease 2019 (COVID-19). Recent research found that countries with universal BCG childhood vaccination policies tend to be less affected by the COVID-19 pandemic. However, such ecological studies are biased by numerous confounders. Instead, this paper reports on a rare nationwide natural experiment that occurred in Sweden in 1975, where discontinuation of newborns' BCG vaccination led to a dramatic decrease in BCG coverage rate, thus allowing us to estimate BCG's effect without the biases associated with cross-country comparisons. METHODS: Numbers of COVID-19 cases and hospitalizations were recorded for birth cohorts born just before and just after 1975, representing 1 026 304 and 1 018 544 individuals, respectively. We used regression discontinuity to assess the effect of BCG vaccination on COVID-19-related outcomes. On such a large population, this method allows for a precision that would be hard to achieve using a randomized controlled trial. RESULTS: The odds ratios (95% CI) for COVID-19 cases and COVID-19-related hospitalizations were 1.0005 (.8130-1.1881) and 1.2046 (.7532-1.6560), allowing us to reject fairly modest effects of universal BCG vaccination. We can reject with 95% confidence that universal BCG vaccination reduces the number of cases by 19% and the number of hospitalizations by 25%. CONCLUSIONS: While the effect of a recent vaccination must be evaluated, we provide strong evidence that receiving the BCG vaccine at birth does not have a protective effect against COVID-19 among middle-aged individuals.
引用
- de Chaisemartin C, de Chaisemartin L. Bacille Calmette-Guérin Vaccination in Infancy Does Not Protect Against Coronavirus Disease 2019 (COVID-19): Evidence From a Natural Experiment in Sweden. Clin Infect Dis. 2021. PMID: 32829400. doi:10.1093/cid/ciaa1223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。